Warning! GuruFocus detected
1 Severe warning sign
with NDRA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
ENDRA Life Sciences Inc
NAICS : 334510
SIC : 8071
ISIN : US29273B1044
Share Class Description:
NDRA: Registered ShsDescription
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.02 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 39.1 | |||||
| 3-Year EPS without NRI Growth Rate | -63.7 | |||||
| 3-Year FCF Growth Rate | 39.5 | |||||
| 3-Year Book Growth Rate | -49.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 80.69 | |||||
| 9-Day RSI | 64.96 | |||||
| 14-Day RSI | 55.31 | |||||
| 3-1 Month Momentum % | -9.53 | |||||
| 6-1 Month Momentum % | -36.35 | |||||
| 12-1 Month Momentum % | -99.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.1 | |||||
| Quick Ratio | 6.1 | |||||
| Cash Ratio | 5.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -81.7 | |||||
| Shareholder Yield % | -75.06 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -146.24 | |||||
| ROA % | -115.31 | |||||
| ROIC % | -207.25 | |||||
| 3-Year ROIIC % | 33.19 | |||||
| ROC (Joel Greenblatt) % | -1242.83 | |||||
| ROCE % | -125.51 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.36 | |||||
| Price-to-Tangible-Book | 0.36 | |||||
| EV-to-EBIT | 0.28 | |||||
| EV-to-EBITDA | 0.29 | |||||
| EV-to-Forward-Revenue | 4.88 | |||||
| EV-to-FCF | 0.29 | |||||
| Price-to-Net-Current-Asset-Value | 0.75 | |||||
| Price-to-Net-Cash | 0.81 | |||||
| Earnings Yield (Greenblatt) % | 357.14 | |||||
| FCF Yield % | -335.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NDRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ENDRA Life Sciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -691.421 | ||
| Beta | -0.18 | ||
| 3-Year Sharpe Ratio | -1.4 | ||
| 3-Year Sortino Ratio | -1.59 | ||
| Volatility % | 112.96 | ||
| 14-Day RSI | 55.31 | ||
| 14-Day ATR ($) | 0.359111 | ||
| 20-Day SMA ($) | 4.020465 | ||
| 12-1 Month Momentum % | -99.7 | ||
| 52-Week Range ($) | 3.15 - 1749.999912 | ||
| Shares Outstanding (Mil) | 0.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ENDRA Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ENDRA Life Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ENDRA Life Sciences Inc Frequently Asked Questions
What is ENDRA Life Sciences Inc(NDRA)'s stock price today?
The current price of NDRA is $4.49. The 52 week high of NDRA is $1750.00 and 52 week low is $3.15.
When is next earnings date of ENDRA Life Sciences Inc(NDRA)?
The next earnings date of ENDRA Life Sciences Inc(NDRA) is 2025-03-28 Est..
Does ENDRA Life Sciences Inc(NDRA) pay dividends? If so, how much?
ENDRA Life Sciences Inc(NDRA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers